Cargando…

Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas

BACKGROUND: This study examined the clinical significance of NAC1 and the expression level of its potential downstream target fatty acid synthase (FASN) in ovarian clear cell carcinomas (OCCCs), and evaluated the NAC1/FASN pathway as a potential therapeutic target. METHODS: NAC1 and FASN expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahman, M T, Nakayama, K, Rahman, M, Katagiri, H, Katagiri, A, Ishibashi, T, Ishikawa, M, Iida, K, Nakayama, N, Otsuki, Y, Nakayama, S, Miyazaki, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394978/ https://www.ncbi.nlm.nih.gov/pubmed/22653145 http://dx.doi.org/10.1038/bjc.2012.246

Ejemplares similares

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies
por: Rahman, Munmun, et al.
Publicado: (2013)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas
por: Rahman, Mohammed Tanjimur, et al.
Publicado: (2013)

Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas
por: KATAGIRI, HIROSHI, et al.
Publicado: (2015)

Fatty acid synthase: a novel target for antiglioma therapy
por: Zhao, W, et al.
Publicado: (2006)

Identification of thymidylate synthase as a potential therapeutic target for lung cancer
por: Takezawa, K, et al.
Publicado: (2010)

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
por: Seguin, F, et al.
Publicado: (2012)

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma
por: Bilim, V, et al.
Publicado: (2009)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma
por: Nagata, M, et al.
Publicado: (2011)

Mechanisms of Ovarian Cancer Metastasis: Biochemical Pathways
por: Nakayama, Kentaro, et al.
Publicado: (2012)

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
por: Takezawa, K, et al.
Publicado: (2011)

X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary
por: Miyamoto, M, et al.
Publicado: (2014)

Nucleus accumbens-1/GADD45GIP1 axis mediates cisplatin resistance through cellular senescence in ovarian cancer
por: Nakayama, Kentaro, et al.
Publicado: (2017)

MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells
por: Sodek, K L, et al.
Publicado: (2007)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
por: Köbel, M, et al.
Publicado: (2014)

Microwave endometrial ablation as an alternative to hysterectomy for the emergent control of uterine bleeding in patients who are poor surgical candidates
por: Yeasmin, Shamima, et al.
Publicado: (2008)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition
por: Ding, X, et al.
Publicado: (2009)

Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo
por: Duivenvoorden, W C, et al.
Publicado: (2013)

STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
por: Horiguchi, A, et al.
Publicado: (2010)

CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas
por: NAKAYAMA, KENTARO, et al.
Publicado: (2015)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers
por: Al-Attar, A, et al.
Publicado: (2010)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?
por: Dolley-Hitze, T, et al.
Publicado: (2010)

Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells
por: Singh, R K, et al.
Publicado: (2008)

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma
por: Sato, Emi, et al.
Publicado: (2018)

Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
por: Nonomura, Yuki, et al.
Publicado: (2022)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells
por: Leung, T H-Y, et al.
Publicado: (2013)

IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma
por: Matsuoka, Yuichiro, et al.
Publicado: (2016)

C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer
por: Yamaguchi, K, et al.
Publicado: (2010)

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients
por: Nishio, M, et al.
Publicado: (2005)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets
por: Morera, Daley S, et al.
Publicado: (2017)

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
por: Coley, H M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_c0he0css15b8om7np5ccg7gmid